Literature DB >> 19671737

Predictive biomarkers for targeting insulin-like growth factor-I (IGF-I) receptor.

Craig P Carden1, L Rhoda Molife, Johann S de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19671737     DOI： 10.1158/1535-7163.MCT-09-0641

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  7 in total

Review 1.  Defining the pathway to insulin-like growth factor system targeting in cancer.

Authors:  Steven A Rosenzweig; Hanudatta S Atreya
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

2.  Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Richard Lock; Hernan Carol; Christopher L Morton; Stephen T Keir; C Patrick Reynolds; Min H Kang; John M Maris; Catherine Billups; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-12-22       Impact factor: 3.167

3.  Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

Authors:  David Olmos; Sophie Postel-Vinay; L Rhoda Molife; Scott H Okuno; Scott M Schuetze; M Luisa Paccagnella; Gretchen N Batzel; Donghua Yin; Kathryn Pritchard-Jones; Ian Judson; Francis P Worden; Antonio Gualberto; Michelle Scurr; Johann S de Bono; Paul Haluska
Journal:  Lancet Oncol       Date:  2009-12-23       Impact factor: 41.316

4.  The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.

Authors:  L R Molife; P C Fong; L Paccagnella; A H M Reid; H M Shaw; L Vidal; H-T Arkenau; V Karavasilis; T A Yap; D Olmos; J Spicer; S Postel-Vinay; D Yin; A Lipton; L Demers; K Leitzel; A Gualberto; J S de Bono
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

5.  Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.

Authors:  P H S Shaw; T S Maughan; A R Clarke
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

6.  Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.

Authors:  Bogdan Mitran; Mohamed Altai; Camilla Hofström; Hadis Honarvar; Mattias Sandström; Anna Orlova; Vladimir Tolmachev; Torbjörn Gräslund
Journal:  Amino Acids       Date:  2014-11-27       Impact factor: 3.520

7.  IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers.

Authors:  Hesham M Amin; Ajaykumar C Morani; Najat C Daw; Salah-Eddine Lamhamedi-Cherradi; Vivek Subbiah; Brian A Menegaz; Deeksha Vishwamitra; Ghazaleh Eskandari; Bhawana George; Robert S Benjamin; Shreyaskumar Patel; Juhee Song; Alexander J Lazar; Wei-Lien Wang; Razelle Kurzrock; Alberto Pappo; Peter M Anderson; Gary K Schwartz; Dejka Araujo; Branko Cuglievan; Ravin Ratan; David McCall; Sana Mohiuddin; John A Livingston; Eric R Molina; Aung Naing; Joseph A Ludwig
Journal:  Cancers (Basel)       Date:  2020-07-02       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.